The consortium of MATHIAS

MATHIAS has partners in Denmark, France, Germany, Switzerland and United Kingdom. The consortium includes public bodies as well as small enterprises.

MATHIAS partners:

  • Eberhard Karls Universität Tübingen (EKUT) - Coordinator, Germany
  • Universitätsklinikum Essen (UKEssen), Germany
  • ISCA Diagnostics Ltd. (ISCA), United Kigndom
  • CheMatech SAS (CHEMA), France
  • Paul Scherrer Institut (PSI), Switzerland
  • Danmarks Tekniske Universitet (DTU), Denmark

Eberhard Karls Universität Tübingen

The Eberhard Karls Universität Tübingen is one of Europe's oldest universities. Several hundred years of history in the sciences and humanities have been written here. The University and the town of Tübingen are closely interlinked. The town has some 85,000 inhabitants including around 25,000 students from Germany and abroad. No less than 400 full professors and more than 4000 academic and scientific staff teach and carry out research here. Personal contacts and joint projects link them with researchers, working groups and institutions worldwide.

The latest chapter of the University's history is marked by its success in the German federal and state governments' Excellence Initiative. One graduate school, one excellence cluster and the University's institutional strategy were successful in the major funding program - also making Tübingen one of Germany's eleven universities in the top "excellent" class.


Department of Preclinical Imaging and Radiopharmacy


The Department of Preclinical Imaging and Radiopharmacy comprises 57 scientists and staff members covering the entire field of basic and translational imaging science. We focus within the working group of the Werner Siemens Imaging Center (WSIC) on the research related to PET (positron emission tomography) and PET/MRI (magnetic resonance imaging) detector development, radiotracer and fluorescence biomarker development as well as imaging research in various fields of biomedicine such as oncology, neurology, inflammation, infectious disease and cardiology. The department is part of several research projects and consortia dealing with non-invasive imaging and radiotracer development, also due to its excellent infrastructure (PET, MR, Cyclotron), including an unique animal PET/MRT scanner.

Staff

Picture

Prof. Bernd Pichler, PhD
Biomedical Engineer
Coordinator of MATHIAS
Curriculum vitae



Picture

Stefan Wiehr, PhD
Biologist
Group leader




Picture

Andreas Maurer, PhD
Chemist
Tracer development




Picture

Rebecca Rock, PhD
Chemist
Administration and management




Picture

Anna-Maria Rolle
PhD student





Former Staff Members

Picture

Uta Paulsen





Universitätsklinikum Essen

Science and research at the highest international level is the primary aim which the Medical Faculty of the University Duisburg-Essen pursues with ambition. We have dedicated our research priorities to the areas Heart and Circulation, Oncology, Immunology and Infection, Transplantation and Genetic Medicine. On the basis of national and international collaborations our research groups work towards an optimization of clinical diagnostics and treatment. As the Medical Faculty is located at the campus of the University Hospital Essen, scientific research is tightly interwoven with medical practice, directly benefitting patients who will receive the latest available therapies. Every year, about 153,000 outpatients and 44,000 inpatients are treated here and are provided with state-of-the art medical care.


Institute of Experimental Immunology and Imaging (IEII )

The research interest of the Institute of Experimental Immunology and Imaging (IEII) is to characterize the dynamics of immune cell behavior within the course of the immune response in vivo. The IEII employs a wide range of specialized imaging technologies (e.g. intravital 2-photon microscopy) by which we investigate how immune cells function in vivo in important organs such as the lymph node, the bone marrow, the brain and the lung. We have a long standing experience in the animal infection model of invasive aspergillosis demonstrated by seminal discoveries in the field of pulmonary aspergillosis which were made in our lab.
The research of the Institute of Diagnostic and Investigative Radiology and Neuroradiology (IDIRN) is focused on abdominal, cardiovascular and neuroradiological imaging. Latest feasibility studies at IDIRN about ultra high field- and PET/MRI imaging provided an insight into future imaging and diagnostic possibilities which could replace today´s technologies. The Clinic for Nuclear Medicine (CNM) offers all diagnostic procedures in nuclear medicine and additionally produces radiopharmaceuticals for its two positron emission tomography (PET) scanners.
Therefore the IEII delivers all theoretical and practical knowledge to successfully perform a preclinical characterization of Ab tracers in collaboration with the IDIRN and the CNM, both also located at the University Hospital Essen.


Staff

Picture

Prof.Dr. Matthias Gunzer ; PhD
Director of the Institute for Experimental Immunology and Imaging (IEII)
Curriculum vitae




Picture

Dr. Mike Hasenberg; PhD
PostDoc, IEII





Picture

Dr. Juliane Weski; PhD
PostDoc, IEII





Picture

PD Dr.med. Lale Umutlu; MD
Deputy head of the Institute of Diagnostic and Interventional Radiology and Neuroradiology (IDIRN)





Picture

Prof. Dr.med. Ken Herrmann
Director of the Clinic for Nuclear Medicine (CNM)





Picture

Dr. Thorsten Pöppel; MD
Senior physician





Picture

Marcus Brinkmann
Center for Clinical Studies Essen (ZKSE)





Picture

Sophie Henneberg
PhD student





Former Staff Members

Picture

Djamschid Solouk
PhD student





Picture

Prof. Dr. Thomas Lauenstein; MD






Picture

Dr. Karsten Beiderwellen; MD






Picture

Prof. Dr. Dr. Andreas Bockisch





ISCA Diagnostics Ltd.


ISCA logo

Isca Diagnostics is a University of Exeter spin-out company delivering point-of-care tests for the rapid detection of human fungal infections. The establishment of Isca has enabled the company director, Professor Christopher Thornton, to transfer his University R&D activities in hybridoma technology to the medical sector, providing the healthcare profession with easy access to rapid and highly accurate diagnostic tests for human mycoses. Isca's flagship diagnostic is a lateral-flow assay for detection of invasive pulmonary aspergillosis, a frequently fatal disease of immunocompormised patients caused by the environmental mould Aspergillus.

Established in 2012, Isca is a UK medical diagnostics company focused on the research and development of simple, user-friendly, diagnostic tests for human fungal infections, based around highly specific monoclonal antibodies and lateral-flow technology. Lateral-flow devices incorporating patented monoclonal antibodies specific to Aspergillus, Fusarium, Pseudallescheria-Scedosporium complex, Scedosporium prolificans and Trichosporon enable the rapid diagnosis of invasive fungal diseases of humans.

Staff

Picture

Christopher Thornton, PhD; Immunologist
Associate Professor
Curriculum vitae




Picture

Genna Davis, MRes; Biologist
R&D scientist





CheMatech SAS

CheMatech is a unique company in Europe specializing in the design and synthesis of chelating agents for molecular imaging and therapy. CheMatech, founded in 2005, is a spin-off of the Institut of Molecular Chemistry of the University of Burgundy in Dijon, France. Chelating agents such as DOTA, NOTA and NODAGA derivatives are widely used for peptides or antibodies labelling especillay with 67/68Ga, 111In, 64/67Cu.

CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also realizes custom syntheses of new macrocyclic compounds.

Staff

Picture

Frédéric BOSCHETTI, PhD;
CEO and Chemist
Curriculum vitae




Picture

Stéphane Martel, Chemist
Technician





Picture

Guillaume Paulin, Chemist
Technician





Picture

Adrien Dubois, Chemist
PhD student





Paul Scherrer Institut

The Paul Scherrer Institute, PSI, is the largest research centre for natural and engineering sciences within Switzerland. PSI performs world-class research in three main subject areas: Matter and Material; Energy and the Environment; and Human Health. By conducting fundamental and applied research, PSI works on long-term solutions for major challenges facing society, industry and science. The institute's own research activities concentrate on scientific projects that strongly benefit from the use of the large-scale facilities.


Center for Radiopharmaceutical Sciences (CRS)

The main focus of the radiopharmacy research is the development of radioactively labeled molecules which bind specifically in vivo to defined structures (e.g. receptors or antigens). Such functional radiopharmaceuticals can serve both as diagnostic agents in nuclear medicine and as therapeutic agents for use against tumor metastases.
The Center of Radiopharmaceutical Sciences which is sponsored by the three institutions ETH Zurich, PSI (Research Department Biology and Chemistry) and USZ (University Hospital Zurich) is orientated towards clinical application and is based upon an interdisciplinary approach involving radiopharmaceutical chemistry, biochemistry, molecular biology, pharmacy and pharmacology.
At PSI with its powerful and high energy cyclotron as well as respective infrastructure, the main focus is on targeted radionuclide therapy starting from concept to proof of principle.
The research focus at the newly commissioned Animal Imaging Center-PET located at the ETH-Hönggerberg, is on molecular imaging with newly developed and established PET tracers using high resolution small animal PET scanners.
At the USZ the main activities are the development of PET tracers for clinical research and the GMP-syntheses of clinically established PET ligands for routine application in nuclear medicine.

Staff

Picture


Prof. Roger Schibli, PhD
Radiopharmaceutical chemist
Curriculum vitae



Picture

Philipp Spycher, PhD





Danmarks Tekniske Universitet


For almost two centuries DTU, Technical University of Denmark, has been dedicated to fulfilling the vision of H.C. Ørsted - the father of electromagnetism - who founded the university in 1829 to develop and create value using the natural sciences and the technical sciences to benefit society.



The Hevesy Laboratory

The aim of the Hevesy Laboratory is to:

  • Carry out research, development and production of radioactive drugs for diagnostics and treatment
  • Produce radioactive isotopes for use in research and with applications in industry and medicine
The Hevesy Laboratory is named after George de Hevesy (1885 - 1966), who was awarded the Nobel Prize in chemistry in 1943 for his work on the use of isotopes as tracers in the study of chemical processes. At the Hevesy Laboratory, radioactive isotopes are produced by means of a biomedical cyclotron donated by The John and Birthe Meyer Foundation in 2004. Currently the work includes:
  • Development of new diagnostic PET (Positron Emission Tomography) tracers based on F-18
  • Development of new diagnostic radiopharmaceuticals based on short-lived radioactive metals ions conjugated to biomolecules
  • Development and production of new radionuclide therapy agents
  • Research in labelling chemistry to expand the radiochemist's toolbox

Staff

Picture


Mikael Jensen, PhD
Professor
Curriculum vitae





Picture


Jesper Fonslet
PhD student
Curriculum vitae





Former Staff Members

Picture




Gregory Severin, PhD, Physicist